|Table of Contents|

Comparison of the expression of ER,PR,Her-2 and Ki-67 between primary breast cancer and synchronous sentinel lymph node metastasis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 06
Page:
959-963
Research Field:
Publishing date:

Info

Title:
Comparison of the expression of ER,PR,Her-2 and Ki-67 between primary breast cancer and synchronous sentinel lymph node metastasis
Author(s):
Wang Yaohui; Gao Lili; Wang Chenxi; Liu Chunyang; Zhang Yifen
Department of Pathology,Jiangsu Province Hospital of Chinese Medicine,Jiangsu Nanjing 210029,China.
Keywords:
breast cancer; sentinel lymph node; estrogen receptor; progesterone receptor; human epidermal growth factor receptor 2; Ki-67; differential expression
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2019.06.013
Abstract:
Objective:To explore the expression and difference of ER,PR,Her-2 and Ki-67 between primary breast cancer and synchronous sentinel lymph node metastasis.Methods:50 cases of primary breast cancer with synchronous sentinel lymph node metastases were collected.The expression and difference of ER,PR,Her-2 and Ki-67 between primary breast cancer and sentinel lymph node metastasis were discussed by immunohistochemistry and in situ hybridization.Results:The consistent rate of ER between primary breast cancer and SLN metastasis was 100%.The consistent rates of PR and Her-2 between primary breast cancer and SLN metastasis were 92% and 96%,and the inconsistency rates were 8% and 4%,and there were no statistically significant differences(P＞0.05).The expression rate of Ki-67 in primary breast cancer was （30.3±20.2）%,and （25.1±17.6）% in SLN metastasis，the difference was statistically significant (P<0.05).The consistent rates of Ki-67 between primary breast cancer and SLN metastasis were 70%,and the inconsistency rates were 30%,but there was no statistically significant difference(P＞0.05).The positive rate of axillary lymph nodes in the high expression of primary tumors but low in SLN metastasis group was 22.2%(2/9),which was significantly lower than that in the non change group 62.5%(15/24),and the difference was statistically significant (P=0.04).Conclusion:The ER,PR and Her-2 status of primary foci can represent the expression of SLN metastasis basically,however,reevaluate the molecular status of SLN metastases will be beneficial for individuals.The expression of Ki-67 in SLN metastasis decreased,and could predict lower positive status of axillary lymph node possibly.

References:

［1］China Cancer Association breast cancer Specialized Committee.Guidelines for breast cancer diagnosis and treatment of China Cancer Association (2017 Edition) ［J］.Chinese Journal of Cancer,2017,27(9): 659-759.［中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017版)［J］.中国癌症杂志,2017,27(9):659-759.］
［2］Lindstrom LS,Karlsson E,Wilking UM,et al.Clinically used breast cancer markers such as estrogen receptor,progesterone receptor,and human epidermal growth factor receptor 2 are unstable throughout tumor progression［J］.J Clin Oncol,2012,24(2):2601-2608.
［3］Yeung C,Hilton J,Clemons M,et al.Estrogen,progesterone,and HER2/neu receptor discordance between primary and metastatic breast tumours-a review［J］.Cancer Metastasis Rev,2016,35(3):1-11.
［4］Sun YH,Tao WY.Research progress of sentinel lymph node biopsy in breast cancer［J］.Modern Oncology,2017,25(4):634-637.［孙永辉,陶维阳.乳腺癌前哨淋巴结活检研究进展［J］.现代肿瘤医学,2017,25(4):634-637.］
［5］Deyarmin B,Kane JL,Valente AL,et al.Effect of ASCO/CAP guidelines for determining ER status on molecular subtype［J］.Ann Surg Oncol,2013,20(1):87-93.
［6］Prat A,Cheang MC,Martín M,et al.Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer［J］.J Clin Oncol,2013,31(2):203-209.
［7］"Breast cancer HER test guide" compiling group.Breast cancer HER2 test guide (2014 Edition) ［J］.Chinese Journal of Pathology,2014,43(4): 262-267.［《乳腺癌HER检测指南》编写组.乳腺癌HER2检测指南(2014版)［J］.中华病理学杂志,2014,43(4):262-267.］
［8］Goldhirsch A,Winer EP,Coates AS. Personalizing the treatment of women with early breast cancer: highlights of the St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2013［J］.Ann Oncol,2013,24(9):2206-2223.
［9］Rakha EA,Green AR.Molecular classification of breast cancer:What the pathologist needs to know［J］.Pathology,2017,49(2): 111-119.
［10］Koo JS,Jung W,Jeong J.Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site［J］.Tumori,2010,96(3):424-432.
［11］Yao ZX,Lu LJ,Wang RJ,et al.Discordance and clinical significance of ER,PR,and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis［J］.Med Oncol,2014,31(1):1-7.
［12］Liu Qi,Zuo WS,Wang XZ,et al.Correlation analysis of hormone receptors and HER-2 and Ki-67 expression between primary lesions and lymph node metastases in breast cancer tissues ［J］.Chinese Journal of Cancer Prevention and Treatment,2013,20 (15): 1153-1157.［刘琪,左文述,王新昭,等.乳腺癌原发灶和淋巴结转移灶激素受体及HER-2与Ki-67表达相关性分析［J］.中华肿瘤防治杂志,2013,20(15):1153-1157.］
［13］Zhao HB,Cheng XY,Liu JJ,et al.Control study of ER,PR and c-erbB-2 statuses between primary and metastatic axillary lymph nodes of breast cancer［J］.Chinese Journal of Cancer Prevention and Treatment,2011,18(8): 594-596.［赵海波,程雪雁,刘金君,等.乳腺癌原发灶与腋淋巴结转移灶ER和PR及c-erbB-2表达的对照研究［J］.中华肿瘤防治杂志,2011,18(8):594-596.］
［14］Zhao S,Xu L,Liu W,et al.Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer［J］.Int J Clin Exp Pathol,2015,8(5):5744-5748.
［15］Rossi S,Basso M,Strippoli A,et al.Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease［J］.Clin Breast Cancer,2015,15(5):307-312.
［16］Park D,Karesen R,Noren T,et al.Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases:Clinical implications［J］.Virchows Arch,2007,451(1):11-18.
［17］Tawfik K,Kimler BF,Davis MK,et al.Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant［J］.Hum Pathol,2013,44(1):39-46.

Memo

Memo:
江苏省中医院院级课题（编号：Y17063）
Last Update: 1900-01-01